This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dcthttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n18https://global.dbpedia.org/id/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n13http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n15http://commons.wikimedia.org/wiki/Special:FilePath/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
dbchttp://dbpedia.org/resource/Category:
provhttp://www.w3.org/ns/prov#
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:5F-PCN
rdf:type
dbo:Drug dbo:ChemicalSubstance n13:ChemicalObject wikidata:Q8386 owl:Thing
rdfs:label
5F-PCN
rdfs:comment
5F-PCN (also known as 5F-MN-21) is an azaindole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is closely related to NNE1. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of 5F-PCN may release 1-naphthylamine, a known carcinogen.
foaf:depiction
n15:5F-PCN_structure.png
dct:subject
dbc:Pyrrolopyridines dbc:Indolecarboxamides dbc:Designer_drugs dbc:Organofluorides dbc:Naphthoylindoles
dbo:wikiPageID
47309223
dbo:wikiPageRevisionID
1075254400
dbo:wikiPageWikiLink
dbr:AM-2201 dbr:Designer_drug dbr:1-naphthylamine dbr:SDB-005 dbc:Pyrrolopyridines dbc:Indolecarboxamides dbc:Designer_drugs dbr:APICA_(synthetic_cannabinoid_drug) dbc:Organofluorides dbr:5F-NNE1 dbr:Synthetic_cannabinoid dbr:CUMYL-PICA dbr:APINACA dbr:Amantadine dbr:Agonist dbr:CUMYL-5F-P7AICA dbr:NNE1 dbc:Naphthoylindoles dbr:Carcinogen dbr:NM-2201 dbr:CB1_receptor dbr:JWH-018
owl:sameAs
yago-res:5F-PCN n18:2Msdg wikidata:Q25099379
dbp:wikiPageUsesTemplate
dbt:Div_col dbt:Div_col_end dbt:Cannabinoids dbt:Cannabinoid-stub dbt:Reflist dbt:Cascite dbt:Drugbox dbt:Fdacite
dbo:thumbnail
n15:5F-PCN_structure.png?width=300
dbp:c
23
dbp:casNumber
2219332
dbp:chemspiderid
34450856
dbp:f
1
dbp:h
22
dbp:iupacName
1
dbp:legalUk
Class B
dbp:n
3
dbp:o
1
dbp:pubchem
125181244
dbp:smiles
O=CC3=CNC4=C3C=NC=C4
dbp:stdinchi
1
dbp:stdinchikey
BRRZRRZUERBDQL-UHFFFAOYSA-N
dbp:unii
Q7GH2GGJ3E
dbo:abstract
5F-PCN (also known as 5F-MN-21) is an azaindole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is closely related to NNE1. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of 5F-PCN may release 1-naphthylamine, a known carcinogen.
dbp:legalCa
Schedule II
gold:hypernym
dbr:Cannabinoid
prov:wasDerivedFrom
wikipedia-en:5F-PCN?oldid=1075254400&ns=0
dbo:wikiPageLength
3130
dbo:casNumber
2219332-48-4
dbo:fdaUniiCode
Q7GH2GGJ3E
dbo:pubchem
125181244
foaf:isPrimaryTopicOf
wikipedia-en:5F-PCN